Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
While electrosynthesis represents a green and advantageous alternative to traditional synthetic methods, electrochemical reactions still suffer from some drawbacks that require further efforts in order to fully express the potential of electricity-driven transformations. In this Comment, we will briefly discuss both the advantages and limitations of electrosynthesis, especially when compared with the other traditional synthetic organic methods, and share some forward-looking thoughts on the future developments of electrochemical reactions.
Skyrmions in chiral magnets are a particle-like texture that has been attracting growing interest due to their novel dynamics and possible applications. Here, we discuss the role of disorder and skyrmion-skyrmion interaction in governing their motion under an external drive.
A pharmaceutical industry viewpoint on how the fundamental laws of photochemistry are used to identify the parameters required to implement photochemistry from lab to scale. Parameters such as photon stoichiometry and light intensity are highlighted within to inform future publications.
Can organic chemistry mimic nature in efficiency and sustainability? Not yet, but recent developments in photoredox catalysis animated the synthetic chemistry field, providing greener opportunities for industry and academia.
Understanding the cellular adaptation to oxygen deficiency -hypoxia- has a profound impact on our knowledge of the pathogenesis of several diseases. The elucidation of the molecular machinery that regulates response to hypoxia has been awarded the Nobel Prize in Physiology or Medicine.
Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.
